Congratulations to the recipients of the 2017 Patient Advocacy Leadership (PAL) Awards. The global PAL Awards program supports projects by non-profit organizations that serve patients living with lysosomal storage disorders (LSDs), a group of rare, inherited disorders that can cause progressive and debilitating health problems.
In the eight years since the program was started, Sanofi Genzyme has awarded close to $810,000.00 to support 52 unique projects proposed by organizations in 28 different countries across the world. As an independent voice in the lysosomal storage disease community, patient organizations play a vital role in providing leadership, resources and access to care and support for patients and their families around the world. Sanofi Genzyme believes supporting their work is critical to optimizing patient care and meeting the ever-growing needs of the LSD community.
In 2017, 36 patient organizations from across the globe submitted proposals for new collaborative and creative activities to support the LSD patient community. Proposals were received from organizations in 24 countries, across a variety of rare disease groups and communities. Programs from six patient organizations were then selected by an Independent External Review Committee. This year’s award recipients come from Ukraine, the United Kingdom, the United States, Romania, France, and New Zealand.
Each proposal represents a unique approach to meeting the needs of the LSD community. Organizations are eager to empower patients, raise the awareness level about LSDs amongst the public, and study trends in rare diseases.